Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Fabiola De Luca und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological, Pharmaceutical and Environmental Chemistry, University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina,…. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by immunological alterations of myeloid cells and lymphocytes. The first-line therapy involves the use of classic chemotherapy; however, many patients have a relapsed form that could evolve into a refractory MM. The new therapeutic frontiers involve the use of new monoclonal antibodies (Mab) such as daratumumab, isatuximab, and elotuzumab. In addition to monoclonal antibodies, new immunotherapies based on modern bispecific antibodies and chimeric antigen receptor (CAR) T cell therapy have been investigated. For this reason, immunotherapy represents the greatest hope for the treatment of MM. This review intends to focus the attention on the new approved antibody targets. The most important are: CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab), and BCMA (belantamab mafodotin) for the treatment of MM currently used in clinical practice. Although the disease is still incurable, the future perspective is to find the best therapeutic combination among all available drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Biological, Pharmaceutical and Environmental Chemistry, University of Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.
- Department of Human Pathology in Adulthood and Childhood, University of Messina, Via Consolare Valeria, 90100 Messina, Italy.
ORCID-Profile: Alessandro Allegra, Santo Previti, Roberta Ettari
Zitieren
APA
De Luca, F., Allegra, A., Di Chio, C., Previti, S., Zappalà, M., & Ettari, R. (2023). Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043136
Vancouver
De Luca F, Allegra A, Di Chio C, Previti S, Zappalà M, Ettari R. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043136
BibTeX
@article{DeLuca2023,
author = {De Luca, Fabiola and Allegra, Alessandro and Di Chio, Carla and Previti, Santo and Zappalà, Maria and Ettari, Roberta},
title = {Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043136}
}
EUVIMED